3//SEC Filing
OrbiMed Capital GP VI LLC 3
Accession 0001123292-19-000721
CIK 0001661059other
Filed
May 7, 8:00 PM ET
Accepted
May 8, 8:04 PM ET
Size
11.4 KB
Accession
0001123292-19-000721
Insider Transaction Report
Form 3
NextCure, Inc.NXTC
ORBIMED ADVISORS LLC
Director10% Owner
Holdings
- (indirect: See footnotes)
Series A-2 Preferred Stock
→ Common Stock (743,110 underlying) - (indirect: See footnotes)
Series A-3 Preferred Stock
→ Common Stock (729,599 underlying) - (indirect: See footnotes)
Series B-1 Preferred Stock
→ Common Stock (442,438 underlying) - (indirect: See footnotes)
Series A-1 Preferred Stock
→ Common Stock (445,866 underlying)
OrbiMed Capital GP VI LLC
Director10% Owner
Holdings
- (indirect: See footnotes)
Series B-1 Preferred Stock
→ Common Stock (442,438 underlying) - (indirect: See footnotes)
Series A-1 Preferred Stock
→ Common Stock (445,866 underlying) - (indirect: See footnotes)
Series A-2 Preferred Stock
→ Common Stock (743,110 underlying) - (indirect: See footnotes)
Series A-3 Preferred Stock
→ Common Stock (729,599 underlying)
Footnotes (3)
- [F1]The reported securities are convertible into shares of Common Stock on a 1-for-8.0338 basis at the holder's election, will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering, and have no expiration date.
- [F2]These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP LLC ("GP VII") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein.
- [F3]This report on Form 3 is jointly filed by GP VI and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Chau Q. Khuong ("Khuong"), an employee of OrbiMed advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Khuong is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or any other purpose.
Documents
Issuer
NextCure, Inc.
CIK 0001661059
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001682115
Filing Metadata
- Form type
- 3
- Filed
- May 7, 8:00 PM ET
- Accepted
- May 8, 8:04 PM ET
- Size
- 11.4 KB